Clinical Trials Logo
  1. Home
  2. Covid19
  3. NCT04344782

Trial Evaluating Efficacy and Safety of Bevacizumab (Avastin®/Zeribev®) in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort — CORIMMUNO-BEVA  

COVID19 Pneumonia Clinical Trial

Official title:
Cohort Multiple Randomized Controlled Trials Open-label of Immune Modulatory Drugs and Other Treatments in COVID-19 Patients CORIMUNO-19- BEVA Trial

Clinical Trial Summary

Bevacizumab, ZERIBEV® (Pfizer)/AVASTIN® (Roche) 25 mg/ml ®, is a recombinant humanised monoclonal IgG1 antibody It seems interesting to use bevacizumab in severe patients infected with SARS-CoV-2 requiring hospitalization in conventional unit or in ICU.

This protocol CORIMUNO19-BEVA will evaluate the efficacy and safety of AVASTIN®/ ZERIBEV® (bevacizumab) COVID-19 patients hospitalized in conventional units.

This phase 2 randomized clinical trial aimed at evaluating the efficacy and safety of AVASTIN®/ ZERIBEV® (bevacizumab) alone versus standard of care (SoC) in patients hospitalized in conventional units.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04344782
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact Jacques Cadranel, MD PhD
Phone 1 56 01 66 73
Email jacques.cadranel@aphp.fr
Status Not yet recruiting
Phase Phase 2
Start date April 15, 2020
Completion date November 30, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT04565379 - Clinical Trial to Investigate the Efficacy and Safety of NuSepin® in COVID-19 Pneumonia Patients Phase 2
Recruiting NCT04527224 - Study to Evaluate the Efficacy and Safety of AstroStem-V in Treatment of COVID-19 Pneumonia Phase 1/Phase 2
Recruiting NCT03183570 - Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT Early Phase 1
Recruiting NCT04642040 - Effectiveness of Pulmonary Rehabilitation Program in Patients With SARS-CoV-2 Pneumonia N/A
Recruiting NCT04487951 - N-terminal Pro B-type Natriuretic Peptide and Vitamin D Levels as Prognostic Markers in COVID-19 Pneumonia
Active, not recruiting NCT04881214 - COVID-19 Pneumonia: Pulmonary Physiology, Health-related Quality of Life and Benefit of a Rehabilitation Program N/A
Recruiting NCT04377750 - The Use of Tocilizumab in the Management of Patients Who Have Severe COVID-19 With Suspected Pulmonary Hyperinflammation Phase 4
Recruiting NCT04569227 - Prevention of COVID-19 Infection to Severe Pneumonia or ARDS Phase 2
Not yet recruiting NCT04344756 - Trial Evaluating Efficacy and Safety of Anticoagulation in Patients With COVID-19 Infection, Nested in the Corimmuno-19 Cohort Phase 2
Completed NCT04535063 - Convalescent Plasma as Potential Therapy for Severe COVID-19 Pneumonia Phase 3